We hypothesize that the pVAX14 construct is acting as an adjuvant, boosting pre-existing immune responses initiated by the antigens from the malignant cells as evidenced by the increase in anti-RARA antibodies in the APL model and consequent reduction in PML-RARA transcripts. Here, RARA is linked to acute promyelocytic leukemia.